Clover Reports the First Patient Dosing of SCB-2019 as a Heterologous Booster in P-III Trial for the Treatment of COVID-19
- The first patient has been dosed in a P-III study evaluating SCB-2019 (CpG 1018/Alum) in 1200 patients with COVID-19 before vaccination with CoronaVac, Comirnaty, or Vaxzevria. The initial data from 3rd booster groups (CoronaVac, Comirnaty) are expected in Q3’22 & Vaxzevria group in Q4’22
- The results from another study showed that SCB-2019 elicited a rapid response & higher levels of neutralizing Abs against prototype virus & VoC (incl. Omicron) than patients who received three doses of AstraZeneca's COVID-19 vaccine. These universal COVID-19 booster data will be included in the company's regulatory submissions
- The company plans to initiate a subcohort of SCB-2019 as a 4th dose booster with expected initial results in Q4’22
Ref: GlobalNewswire | Image: Clover
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.